{
    "organizations": [],
    "uuid": "d5ad6af29a2cf5a49e9f0f4d423d97e9dd9470cf",
    "author": "",
    "url": "https://www.reuters.com/article/brief-amgen-says-fda-approves-aimovig-a/brief-amgen-says-fda-approves-aimovig-a-treatment-for-migraine-prevention-idUSASC0A2VS",
    "ord_in_thread": 0,
    "title": "BRIEF-Amgen Says FDA Approves Aimovig, A Treatment For Migraine Prevention - Reuters",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 17 (Reuters) - Amgen Inc:\n* FDA APPROVES AIMOVIGâ„¢ (ERENUMAB-AOOE), A NOVEL TREATMENT DEVELOPED SPECIFICALLY FOR MIGRAINE PREVENTION\n* AIMOVIG IS EXPECTED TO BE AVAILABLE TO PATIENTS WITHIN ONE WEEK Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-18T02:44:00.000+03:00",
    "crawled": "2018-05-18T04:22:26.003+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "amgen",
        "inc",
        "fda",
        "approves",
        "novel",
        "treatment",
        "developed",
        "specifically",
        "migraine",
        "prevention",
        "aimovig",
        "expected",
        "available",
        "patient",
        "within",
        "one",
        "week",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}